Search clinical trials for: Zika Virus Purified Inactivated Vaccine (ZPIV)

Total 96 results

National Institute of Allergy and Infectious Diseases...

Completed

Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

Zika Virus Infection

Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

ZIKA Vaccine in Naive Subjects

Zika Virus Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Zika Virus Infection

United States
Kathryn Stephenson
National Institute of Allergy and Infectious Diseases (NIAID); Walter Reed...

Completed

Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study (Z001)

Zika

United States
Takeda

Withdrawn

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Healthy Volunteers

United States
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (VRV12)

Rabies (Healthy Volunteers)

Thailand
Bharat Biotech International Limited

Completed

Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine

Chikungunya

India
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine

Rabies | Rabies Virus

China
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Withdrawn

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Dengue

United States
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above

Influenza

Czech Republic, Philippines, South Africa, Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults

Rabies

France
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
Yisheng Biopharma (Singapore) Pte. Ltd.

Active, not recruiting

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.

Covid-19 Vaccine

United Arab Emirates, Philippines
Valneva Austria GmbH

Completed

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Butantan Institute
Fundação Butantan

Recruiting

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Influenza, Human

Brazil
Novartis Vaccines

Completed

Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules

Rabies

India
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Influenza | Influenza Immunisation

United States
Valneva Austria GmbH

Completed

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Japanese Encephalitis
GlaxoSmithKline

Completed

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Cervical Cancer | Precancerous Condition

Costa Rica
National Institute of Allergy and Infectious Diseases...

Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Influenza | Influenza Immunisation | Avian Influenza

United States
Valneva Austria GmbH

Completed

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
National Institute of Allergy and Infectious Diseases...

Completed

Age and Response to Flu Vaccines

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Influenza | Influenza Immunisation

United States
The Cleveland Clinic

Completed

Influenza Vaccination in Bone Marrow Transplantation

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Development of Childhood Anti-Influenza Immunity

Influenza | Influenza Immunisation

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)

Influenza

France
National Institute of Allergy and Infectious Diseases...

Completed

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

Rabies

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland

Rabies (Healthy Volunteers)

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Efficacy and Safety of Dengue Vaccine in Healthy Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
Valneva Austria GmbH

Completed

Safety Surveillance After Immunization With IXIARO

Japanese Encephalitis

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype

United States
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

Rabies

United States
U.S. Army Medical Research and Development Command

Completed

TDENV PIV and LAV Dengue Prime-boost Strategy

Dengue

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Valneva Austria GmbH

Completed

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years (QIV)

Influenza

China
Pfizer

Completed

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Encephalitis, Tick-Borne

Poland
Pfizer

Completed

Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

Encephalitis, Tick-borne

Belgium
Pfizer

Completed

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

Encephalitis, Tick-borne

Austria
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Influenza

Switzerland

3

Subscribe